Lv4
420 积分 2023-10-13 加入
Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study
23天前
已完结
The current and emerging immunotherapy paradigm in small-cell lung cancer
1个月前
已完结
Emerging Strategies for the Treatment of Small Cell Lung Cancer
1个月前
已完结
The next generation of immunotherapies for lung cancers
1个月前
已完结
Small Cell Lung Cancer: A Review
1个月前
已完结
A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results
4个月前
已完结
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
4个月前
已完结
Exploring the next generation of antibody–drug conjugates
4个月前
已完结
Antibody–drug conjugates come of age in oncology
4个月前
已完结
HER2-targeted therapies beyond breast cancer — an update
4个月前
已完结